CSL Limited has released its FY26 results marked by significant portfolio impairments that obscured underlying operational progress. The company reported a net loss of $2.6 billion on revenue of $15.8 billion, but underlying net profit after tax reached $2.8 billion, reflecting the company’s actual operational performance after adjusting for $7.1 billion in non-cash impairment charges, predominantly at the CSL Vifor segment.
The year represented a deliberate reset under interim CEO Gordon Naylor, with the company prioritizing strategic transformation and operational efficiency over reported earnings. The CSL Behring segment, which contributes over 72 percent of revenue, showed resilience with stable revenue at $11.4 billion as robust immunoglobulin demand offset challenges from Medicare Part D impacts and normalizing channel inventory. More positively, the company achieved strong uptake of newer products ANDEMBRY and HEMGENIX, with the latter growing 25 percent on a constant currency basis, signaling emerging growth drivers in haemophilia treatment.
CSL Vifor, by contrast, faced substantial structural headwinds that led to the $4.1 billion goodwill impairment. Revenue declined 7 percent to $2.4 billion as generic competition pressured iron products, while the TDAPA patent expiry on VELPHORO and the revocation of TAVNEOS marketing authorization represented material portfolio setbacks. Management’s decision to write down this segment reflects a realistic assessment of competitive dynamics and reimbursement pressures in nephrology and iron therapy markets.
The CSL Seqirus segment delivered the strongest relative performance with 8 percent revenue growth to $2.0 billion, driven by successful geographic expansion, real-world evidence supporting FLUCELVAX and FLUAD differentiation, and the recent UK approval of AUJEMFLU. This segment’s outperformance shows the strategic value of product differentiation in mature vaccine markets.
Management delivered $176 million in cost savings while maintaining the dividend and completing a A$1 billion share buyback. Cashflow from operations reached $3.5 billion, supporting continued capital investment despite restructuring activity. Net debt to EBITDA improved to 1.8 times, positioning the company with capacity for growth investment.
A rules-based approach to leveraged ETFs
See how our quantitative strategy works and who it suits.
Explore the strategyBecome an authorised representative
Advise your clients under an established AFSL without building your own. Choose AR or CAR.
Become an AR or CARFor FY27, management projects revenue growth in-line with FY26 at constant currency, with underlying profit growth of approximately 5 percent. CSL Behring is guided to return to mid-single digit revenue growth, supported by continued immunoglobulin expansion and new product momentum. Vifor is expected to decline approximately 25 percent as portfolio headwinds persist. Investors should monitor HEMGENIX penetration in haemophilia markets and AUJEMFLU uptake across geographies, as these products represent the company’s primary near-term growth catalysts following the Vifor restructuring.
View the full ASX announcement (PDF)
About CSL Limited (ASX: CSL)
CSL Limited is a global biotechnology company that develops and delivers innovative biotherapies and vaccines. It is a leader in plasma-derived therapies and one of the largest influenza vaccine manufacturers worldwide.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
Learn to trade with a plan
Our free 5-day course covers entries, exits and risk management.
Start the free courseBecome an authorised representative
Advise your clients under an established AFSL without building your own. Choose AR or CAR.
Become an AR or CAR